Arthroplasty, Replacement, HipLFITNCT00510458
LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study
A study testing LFIT™ Femoral Heads With X3® Insert in people with Arthroplasty, Replacement, Hip, run by Stryker Orthopaedics at 5 sites in United States.
Trial summary
Total hip replacement surgery is considered to be a very successful surgical procedure for the treatment of degenerative joint disease. The purpose of the study is to evaluate a large size (36mm, 40mm or 44mm) femoral (hip) head called the LFIT™ Anatomic CoCr Femoral Head (Low Friction Ion Treatment). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arthroplasty, Replacement, Hip
- What is being tested?
- LFIT™ Femoral Heads With X3® Insert
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 89 participants
- Where
- 5 sitesUnited States
- Study dates
- Apr 2007to Dec 2016
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is candidate for a primary cementless total hip replacement, and a posterolateral surgical approach is planned.
- Patient's preoperative templating predicts the use of a Hemispherical Acetabular Shell size 52mm or larger.
- Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD). Patient must have diagnosis of osteoarthritis (OA), traumatic arthritis (TA), avascular necrosis (AVN), slipped capital epiphysis, pelvic fracture, femoral fracture, failed fracture fixation, or diastrophic variant
- Patient is a male or non-pregnant female age 18 years or older at time of enrollment.
- Patient has signed an IRB approved, study specific Informed Patient Consent Form.
- Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.
Who cannot join
- Patient has an active infection within the affected hip joint.
- Patient requires revision surgery of a previously implanted total hip arthroplasty or hip fusion to the affected joint.
- Patient has a Body Mass Index (BMI) ≥ 40.
- Patient has a neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device.
- Patient is diagnosed with systemic disease or current life threatening illness and is not able to carry on normal activities of daily life (i.e. Paget's disease, renal osteodystrophy, rheumatoid arthritis).
- Patient is immunologically suppressed or receiving chronic steroids in excess of 5mg per day.
- Patient has a recent history of substance dependency that may result in deviations from the evaluation schedule.
- Patient is a prisoner.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United States5 sites
The Center: Orthopedic & Neurosurgical Care & Research
Bend, Oregon, 97701
Tufts Medical Center
Boston, Massachusetts, 02111
Cedars Medical Center University of Miami
Miami, Florida, 33136
Greater Pittsburgh Orthopaedic Associates
Moon Township, Pennsylvania, 15108
Seaview Orthopedics
Ocean City, New Jersey, 07712
About this study
Official title: LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study - An Open Label, Prospective, Post-market, Multi-center Clinical Evaluation of the LFIT™ Anatomic CoCr Femoral Heads With X3® Inserts
Total hip replacement surgery is considered to be a very successful surgical procedure for the treatment of degenerative joint disease. The purpose of the study is to evaluate a large size (36mm, 40mm or 44mm) femoral (hip) head called the LFIT™ Anatomic CoCr Femoral Head (Low Friction Ion Treatment). The large size femoral heads will be used with the Trident® X3® polyethylene (plastic) inserts and will be compared with a historical control. Study Hypothesis: The linear wear rate for hips implanted with the LFIT™ Anatomic CoCr Femoral Head is no worse than 0.08 mm wear per year at 5 years post-surgery.
- Conditions
- Arthroplasty, Replacement, Hip
- Being tested
- LFIT™ Femoral Heads With X3® Insert
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LFIT™ Femoral Heads With X3® InsertDevice
LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
| Study group | Role | What they receive |
|---|---|---|
| LFIT™Femoral Heads With X3® Insert | Other | LFIT™ Femoral Heads With X3® Insert Receives: Device: LFIT™ Femoral Heads With X3® Insert |
What is being measured
The primary outcome is the main question the study is designed to answer.
Linear Wear Rate
Linear wear rate is defined as the annual rate of removal of the polyethylene from the X3 polyethylene insert mated with LFIT™ Anatomic CoCr Femoral Heads determined by comparing digitized images of serial radiographs obtained over the follow-up period.
.
Measured: 5 Years Post-Surgery
Secondary outcomes (8)
Change in Harris Hip Score (HHS) From Pre-operative to Post-operative Visits
The change in HHS is reported by comparing the mean preoperative, 1, 3, and 5 year scores. The HHS assesses pain, function, joint deformity and range of motion. Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score of less than or equal to 79 is considered fair-poor.
90-100 = excellent 80-89 = good 70-79 = fair 0-69 = poor
Measured: preoperative, 1, 3, and 5 years
Change in Harris Hip Score (HHS) Pain Score From Pre-operative to Post-operative Visits
This subscore of the overall HHS provides the patient with 6 possible answers to choose from ranging from, no pain/ignores it, to totally disabled/crippled/pain in bed/bedridden. A maximum of 44 points is possible for this subscore indicating no pain/ignores it.
Pain:
- None or ignores it = 44 points
- Slight, occasional, no compromise in activities = 40 points
- Mild pain, no effect on average activities, rarely moderate pain with unusual activity, may take aspirin = 30 points
- Moderate pain, tolerable but makes concessions to pain. Some limitation of ordinary activity or work. May require occasional pain medicine stronger than aspirin = 20 points
- Marked pain, serious limitation of activities = 10 points
- Totally disabled, crippled, pain in bed, bedridden = 0 points
Measured: preop, 1, 3, and 5 Years
Change in Harris Hip Score (HHS) Range of Motion (ROM) Score From Pre-operative to Post-operative Visits.
This subscore of the overall HHS includes the total points awarded for five different ranges of motion (flexion, abduction, external rotation, internal rotation, adduction). Subscore range is minimum of 0 to maximum of 5 points; the higher the value, the better the outcome.
Flexion:
0-45 degrees x 1.0 index value = max 45 points
45-90 degrees x 0.6 index = max 27 points
90-110 degrees x 0.3 index = max 6 points
110-130 degrees = max 0 points
Abduction:
0-15 degrees x 0.8 index = max 12 points
15-20 degrees x 0.3 index = max 1.5 points
20-45 degrees x 0 index = max 0 points
External Rotation in extension:
0-15 degrees x 0.4 index = max 6 points
Over 15 degrees = max 0 points
Internal Rotation in extension:
Any = max 0 points
Adduction:
0-15 degrees x 0.2 index = max 3 points
Over 15 degrees - max 0 points
To determine the over-all rating for range of motion, multiply the sum of the index values x 0.05.
Measured: preoperative, 1, 3, and 5 Years
Change in SF-12 Health Survey Score (Physical and Mental) From Pre-operative to Post-operative Intervals.
The change in SF-12 is reported by comparing the mean preoperative, 1, 3, and 5 year scores. The SF-12 Health Survey is a 12 item patient completed questionnaire to measure general health and well-being. It includes a physical component score and mental status component score; each ranging from 0-100. Low values represent a poor health state and high values represent a good health state.
Measured: preop, 1, 3, and 5 Years
Change in Lower Extremity Activity Scale (LEAS) From Pre-operative to Post-operative
The change in LEAS is reported by comparing the mean pre-operative, 1,3,and 5 year scores. The LEAS completed by the participant to assess activity level. Activity levels were ordered in terms of intensity from 1 to 18, with 18 indicating the highest activity level.
Measured: preoperative, 1, 3, and 5 Years
Number of Hips That Dislocated
The number of hips that experienced a hip dislocation.
Measured: 3 and 5 years
Number of Hips Evaluated as Radiographically Unstable
Radiographic instability is defined as having any of the following findings on x-ray:
- Radiographic indication of progressive radiolucent lines ≥ 2 mm in thickness around the entire acetabular component
- Radiographic indication of migration of ≥ 3 mm or ≥ 5° of the acetabular component
- Radiographic indication of progressive radiolucent lines ≥ 2 mm thickness around the entire femoral component
- Radiographic indication of progressive subsidence of the femoral component of ≥ 5 mm.
Measured: 1, 3, 5 years
Percentage of Cases That Did Not Have Any Component Revised
A revision is defined as surgical removal and replacement of the femoral bearing head or femoral stem components, or the acetabular shell or acetabular polyethylene liner.
The 97.42% estimate is obtained by Kaplan-Meier method.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Aug 2007 (estimated)
- Study startApr 2007
- Primary completionDec 2016
- Study completionDec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Arthroplasty, Replacement, HipStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 89 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stryker Orthopaedics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- James D'Antonio, MD, Study chair, Greater Pittsburgh Orthopaedic AssociatesStephen Thomas, M.D., Principal investigator, Greater Pittsburgh Orthopaedic AssociatesEric Smith, M.D., Principal investigator, Tufts University Medical CenterArthur Mark, M.D., Principal investigator, Seaview Orthopaedic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00510458
- Sponsor's protocol ID
- 63
- Acronym
- LFIT
- Status last verified
- Jan 2018
- First submitted
- 1 Aug 2007
- Last updated
- 12 Mar 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study - An Open Label, Prospective, Post-market, Multi-center Clinical Evaluation of the LFIT™ Anatomic CoCr Femoral Heads With X3® Inserts
- ClinicalTrials.gov ID
- NCT00510458
- Acronym / sponsor ID
- LFIT / 63
- Conditions
- Arthroplasty, Replacement, Hip
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 89 participants (actual)
- Lead sponsor
- Stryker OrthopaedicsIndustry (pharma, biotech, devices)
- Study start
- Apr 2007
- Primary completion
- Dec 2016 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 2 Aug 2007 (estimated)
- Results
- Posted 12 Mar 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Total hip replacement surgery is considered to be a very successful surgical procedure for the treatment of degenerative joint disease. The purpose of the study is to evaluate a large size (36mm, 40mm or 44mm) femoral (hip) head called the LFIT™ Anatomic CoCr Femoral Head (Low Friction Ion Treatment). The large size femoral heads will be used with the Trident® X3® polyethylene (plastic) inserts and will be compared with a historical control. Study Hypothesis: The linear wear rate for hips implanted with the LFIT™ Anatomic CoCr Femoral Head is no worse than 0.08 mm wear per year at 5 years post-surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| LFIT™Femoral Heads With X3® Insert | Other | Device: LFIT™ Femoral Heads With X3® InsertLFIT™ Femoral Heads With X3® Insert |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patient is candidate for a primary cementless total hip replacement, and a posterolateral surgical approach is planned.
- Patient's preoperative templating predicts the use of a Hemispherical Acetabular Shell size 52mm or larger.
- Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD). Patient must have diagnosis of osteoarthritis (OA), traumatic arthritis (TA), avascular necrosis (AVN), slipped capital epiphysis, pelvic fracture, femoral fracture, failed fracture fixation, or diastrophic variant
- Patient is a male or non-pregnant female age 18 years or older at time of enrollment.
- Patient has signed an IRB approved, study specific Informed Patient Consent Form.
Key exclusion criteria (8 listed)
- Patient has an active infection within the affected hip joint.
- Patient requires revision surgery of a previously implanted total hip arthroplasty or hip fusion to the affected joint.
- Patient has a Body Mass Index (BMI) ≥ 40.
- Patient has a neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device.
- Patient is diagnosed with systemic disease or current life threatening illness and is not able to carry on normal activities of daily life (i.e. Paget's disease, renal osteodystrophy, rheumatoid arthritis).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LFIT™ Femoral Heads With X3® InsertLFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement | Device | LFIT™Femoral Heads With X3® Insert |
Primary outcome
Linear Wear Rate
Time frame: 5 Years Post-Surgery
Linear wear rate is defined as the annual rate of removal of the polyethylene from the X3 polyethylene insert mated with LFIT™ Anatomic CoCr Femoral Heads determined by comparing digitized images of serial radiographs obtained over the follow-up period. .
8 secondary outcomes
Change in Harris Hip Score (HHS) From Pre-operative to Post-operative Visits
Time frame: preoperative, 1, 3, and 5 years
Change in Harris Hip Score (HHS) Pain Score From Pre-operative to Post-operative Visits
Time frame: preop, 1, 3, and 5 Years
Change in Harris Hip Score (HHS) Range of Motion (ROM) Score From Pre-operative to Post-operative Visits.
Time frame: preoperative, 1, 3, and 5 Years
Change in SF-12 Health Survey Score (Physical and Mental) From Pre-operative to Post-operative Intervals.
Time frame: preop, 1, 3, and 5 Years
Change in Lower Extremity Activity Scale (LEAS) From Pre-operative to Post-operative
Time frame: preoperative, 1, 3, and 5 Years
Number of Hips That Dislocated
Time frame: 3 and 5 years
Number of Hips Evaluated as Radiographically Unstable
Time frame: 1, 3, 5 years
Percentage of Cases That Did Not Have Any Component Revised
Time frame: 5 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Arthroplasty, Replacement, Hip
Not yet recruiting
Total Hip Replacement: an Investigation of Robotic-assisted Versus conVentional Surgery and Patient-centred outcomEs
Osteo Arthritis Knee and Hip
RecruitingObservational study
The restor3d Outcomes Registry
Joint Replacement, Arthropathy
RecruitingPhase 4
Low-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty
Pain, Postoperative, Muscle Weakness
Not yet recruitingObservational study
Preoperative Muscle Stiffness, Functional Reserve, and Postoperative Quality of Recovery in Lower Extremity Arthroplasty
Osteoarthritis (Knee / Hip), Sarcopenia
RecruitingObservational study
Z1 Hip System: Post-Market Clinical Follow Up Study
Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James D'Antonio, MD study chair
Greater Pittsburgh Orthopaedic Associates
Stephen Thomas, M.D. principal investigator
Greater Pittsburgh Orthopaedic Associates
Eric Smith, M.D. principal investigator
Tufts University Medical Center
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing LFIT™ Femoral Heads With X3® Insert in people with Arthroplasty, Replacement, Hip, run by Stryker Orthopaedics at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Mar 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Linear Wear Rate (time frame: 5 Years Post-Surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2018.